Zacks Investment Research downgraded shares of H. Lundbeck A/S- (OTCMKTS:HLUYY) from a buy rating to a hold rating in a research report report published on Thursday morning.
According to Zacks, “H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of pharmaceuticals across the world. Its products are targeted at disorders like depression and anxiety, schizophrenia, insomnia, Huntington’s, epilepsies, Alzheimer’s and Parkinson’s diseases. The Company is involved in the development of new and improved drugs for the treatment of psychiatric and neurological disorders. H. Lundbeck A/S is headquartered in Copenhagen, Denmark. “
H. Lundbeck A/S- (HLUYY) opened at $47.66 on Thursday. H. Lundbeck A/S- has a 52-week low of $38.21 and a 52-week high of $66.67. The stock has a market capitalization of $9,486.63, a P/E ratio of 22.06, a PEG ratio of 0.99 and a beta of 0.19. The company has a debt-to-equity ratio of 0.08, a current ratio of 1.21 and a quick ratio of 0.93.
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for H. Lundbeck A/S- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H. Lundbeck A/S- and related companies with MarketBeat.com's FREE daily email newsletter.